Ailanthone targets p23 to overcome MDV3100 resistance in castration-resistant prostate cancer.
about
Ailanthone: a new potential drug for castration-resistant prostate cancer.Dioscin induces prostate cancer cell apoptosis through activation of estrogen receptor-β.Androgen receptor splice variants bind to constitutively open chromatin and promote abiraterone-resistant growth of prostate cancer.Determining direct binders of the Androgen Receptor using a high-throughput Cellular Thermal Shift Assay.Evidence for Hsp90 Co-chaperones in Regulating Hsp90 Function and Promoting Client Protein Folding.Ailanthone inhibits non-small cell lung cancer cell growth through repressing DNA replication via downregulating RPA1.
P2860
Ailanthone targets p23 to overcome MDV3100 resistance in castration-resistant prostate cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 December 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Ailanthone targets p23 to over ...... ion-resistant prostate cancer.
@en
Ailanthone targets p23 to over ...... ion-resistant prostate cancer.
@nl
type
label
Ailanthone targets p23 to over ...... ion-resistant prostate cancer.
@en
Ailanthone targets p23 to over ...... ion-resistant prostate cancer.
@nl
prefLabel
Ailanthone targets p23 to over ...... ion-resistant prostate cancer.
@en
Ailanthone targets p23 to over ...... ion-resistant prostate cancer.
@nl
P2093
P2860
P50
P356
P1476
Ailanthone targets p23 to over ...... ion-resistant prostate cancer.
@en
P2093
Haigang Wu
Huang Chen
Jinhua Wang
Meichun Hu
Mingyao Liu
Shihong Peng
Shuman Gao
Xiaonan Cong
P2860
P2888
P356
10.1038/NCOMMS13122
P407
P577
2016-12-13T00:00:00Z